ArticleJournal of the National Cancer Institute2019
Trends in BRCA Test Utilization in an Integrated Health System, 2005-2015.
Article in Journal of the National Cancer Institute, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05142033 (Implementation of Comprehensive Molecular Profiling and Deep Clinical Annotation of Electronic Health Records in Participants Diagnosed With or at Risk of Developing Cancer), which is not on this map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Implementation of Comprehensive Molecular Profiling and Deep Clinical Annotation of Electronic Health Records in Participants Diagnosed With or at Risk of Developing Cancer (ASAP Study)
Who cites it
25 citing papers in PubMed, 40 citations in OpenAlex.
- All HER2-negative breast cancer patients need gBRCA testing: cost-effectiveness and clinical benefits.British journal of cancer · 2023Trial
- Precision nutrition testing is the future of personalized care: evidence and coverage policies for equitable access.Health affairs scholar · 2026Article
- Homologous Recombination Deficiency and Survival in Ovarian High-Grade Serous Carcinoma by Self-Reported Race.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2025Article
- Patient characteristics, treatment patterns, and clinical outcomes in HER2-negative early breast cancer by germline BRCA status.Future oncology (London, England) · 2025Observational
- Trends in the Utilization ofCurrent oncology (Toronto, Ont.) · 2025Article
- Barriers to early detection: Insurance denials for breast MRI screening in women with germline BRCA1/2 mutations.Gynecologic oncology · 2025Article
- Multi-Gene Panel Testing for Hereditary Cancer Predisposition Among Patients Sixty-Five Years and Above Diagnosed With Breast Cancer.World journal of oncology · 2024Article
- Screening and Testing for Homologous Recombination Repair Deficiency (HRD) in Breast Cancer: an Overview of the Current Global Landscape.Current oncology reports · 2024Review
- Disparities in Genetic Testing for Neurologic Disorders.Neurology · 2024Article
- Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer.Journal of the National Comprehensive Cancer Network : JNCCN · 2023Article
- Germline Genetic Testing in Breast Cancer: Systemic Therapy Implications.Current oncology reports · 2022Review
- Statewide trends and factors associated with genetic testing for hereditary cancer risk in Arkansas 2013-2018.Hereditary cancer in clinical practice · 2022Article
- Psychosocial impact of proactive rapid genetic counseling following breast cancer diagnosis.Psycho-oncology · 2022Article
- PARP inhibition in breast cancer: progress made and future hopes.NPJ breast cancer · 2022Article
- Genetic Evaluation for Hereditary Cancer Syndromes Among African Americans: A Critical Review.The oncologist · 2022Review
- Perspectives on Ovarian Cancer 1809 to 2022 and Beyond.Diagnostics (Basel, Switzerland) · 2022Article
- Precision Medicine forCancers · 2022Review
- Retrospective assessment of barriers and access to genetic services for hereditary cancer syndromes in an integrated health care delivery system.Hereditary cancer in clinical practice · 2022Article
- Cancer Previvors in an Active Duty Service Women Population: An Opportunity for Prevention and Increased Force Readiness.Military medicine · 2021Article
- The Screen Project: Guided Direct-To-Consumer Genetic Testing for Breast Cancer Susceptibility in Canada.Cancers · 2021Article
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
Abstract
backgroundGenetic testing to determine BRCA status has been available for over two decades, but there are few population-based studies of test diffusion. We report 10-year trends in BRCAtesting in an integrated health-care system with long-standing access to genetic services.
methodsA cohort of women aged 18 years and older was created to ascertain BRCA testing (n = 295 087). Annual testing rates between 2005 and 2015 were calculated in all women with and without incident (ie, newly diagnosed) breast and ovarian cancers and in clinically eligible subgroups by family cancer history, personal cancer history, and age at diagnosis. Secular trends were assessed using Poisson regression. Women tested early (2005-2008), midway (2009-2012), and late (2013-2015) in the study period were compared in cross-sectional analyses.
resultsBetween 2005 and 2015, annual testing rates increased from 0.6/1000 person-years (pys) (95% confidence interval [CI] = 0.4 to 0.7/1000 pys) to 0.8/1000 pys (95% CI = 0.6 to 1.0/1000 pys) in women without incident breast or ovarian cancers. Rates decreased from 71.5/1000 pys (95% CI = 42.4 to 120.8/1000 pys) to 44.4/1000 pys (95% CI = 35.5 to 55.6/1000 pys) in women with incident diagnoses, despite improvements in provision of timely BRCA testing during this time frame. We found no evidence of secular trends in clinically eligible subgroups including women with family history indicating increased hereditary cancer risk, but no personal cancer history. At the end of the study period, 97.0% (95% CI = 96.6% to 97.3%) of these women remained untested.
conclusionMany eligible women did not receive BRCA testing despite having insurance coverage and access to specialty genetic services, underscoring challenges to primary and secondary hereditary cancer prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.